CD274 and gastric cancer: Indeed, PD-L1/PD-1 inhibition can substantially improve the outcome of these kinds of GC patients, the problem to be solved is to better identify the patients and the corresponding inclusion criteria for PD-L1/PD-1 therapy, while further clinical trials are needed to explore such specific biomarkers (114).